Drew Ranieri
Stock Analyst at Morgan Stanley
(1.20)
# 3,704
Out of 5,008 analysts
167
Total ratings
44.44%
Success rate
-12.7%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $59.31 | +14.65% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.13 | +45.28% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $13.45 | -25.65% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $369.24 | +20.52% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $15.33 | +23.94% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $14.43 | +87.11% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.00 | +33.33% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $24.06 | -8.56% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $10.65 | -24.88% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $15.01 | +449.63% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.42 | +86.09% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $49.26 | +94.88% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.30 | +130.09% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $192.53 | +53.22% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $126.89 | +120.66% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.65 | -24.81% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $22.90 | +205.68% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $440.94 | -31.96% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $59.31
Upside: +14.65%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.13
Upside: +45.28%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $13.45
Upside: -25.65%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $369.24
Upside: +20.52%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $15.33
Upside: +23.94%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $14.43
Upside: +87.11%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.00
Upside: +33.33%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $24.06
Upside: -8.56%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $10.65
Upside: -24.88%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $15.01
Upside: +449.63%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.42
Upside: +86.09%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $49.26
Upside: +94.88%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.30
Upside: +130.09%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $192.53
Upside: +53.22%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $126.89
Upside: +120.66%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.65
Upside: -24.81%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $22.90
Upside: +205.68%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $440.94
Upside: -31.96%